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Oleoylethanolamine (OEA), an endogenous high-afﬁnity agonist of peroxisome proliferator-activated
receptor alpha (PPAR-a), has revealed the pharmacological properties in the treatment of obesity,
atherosclerosis and other diseases through the modulation of lipid metabolism. To assess whether OEA
can also regulate non-alcoholic fatty liver disease (NAFLD) caused by fat accumulation, we administrated
OEA or fenoﬁbrate in Sprague Dawley (SD) rats fed with a high fat diet (HFD). After 6 or 17 weeks
treatment, OEA (5 mg/kg/day, i.p.) relieved the development of NAFLD compared with control groups by
regulating the levels of plasma TG, TC, ALT and AST and liver inﬂammatory cytokines. Gene expression
analysis of liver tissue and plasma from the animal models showed that OEA and fenoﬁbrate both
promoted the lipid b-oxidation by activating PPAR-a. Detailed research revealed that OEA inhibited the
mRNA expression of lipogenesis in a PPAR-a-independant manner, while fenoﬁbrate expressed an
opposite effection. In summary, our research results suggested that as a potential lead compound, OEA
could improve HFD-induced NAFLD with higher efﬁcacy and safety than fenoﬁbrate.
© 2014 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. All rights reserved.Introduction
Non-alcoholic fatty liver disease (NAFLD) is the most common
chronic liver disease which affects 25e30% of the world's popula-
tion. Onset of NAFLD manifests as large lipid droplet accumulation
in liver cells and triggers the formation of obesity, type II diabetes,
hyperlipidemia, insulin resistance and other metabolic syndromes
(1). The important early metabolic events leading to NAFLD can be
best described as a “two-hit” theory. The “ﬁrst hit” is characterized
by the deposition of triglycerides in hepatocyte during the patho-
logic process of obesity or insulin resistance. The disease is sensitive
to additional cellular events as oxidative stress, lipid peroxidation,
pro-inﬂammatory cytokines release (the “second hit”), which leads
the progress of nonalcoholic steatohepatitis. Current clinical ther-
apies for NAFLD is limited to control of associated metabolic syn-
dromes, reduction risk of cardiovascular disease, and suggestions of
lifestyle changes. So, although dietary control, exercise, insulin-
sensitizing drugs, antioxidants and lipid-lowering drugs can doacological Society.
Production and hosting by Elseviefavor for NAFLD (2), other modalities of treatment is suggested by
clinical observations.
Peroxisome proliferator-activated receptor alpha (PPAR-a) is
predominantly distributed in the active metabolic tissues, such as
liver, kidney, heart and skeletal muscle, in which modulates the
lipid metabolism and energy balance. PPAR-a activation not only
up-regulates the expression levels of carnitine palmitoyl trans-
ferase 1 (CPT1) to promote fatty acid b-oxidation and reduces tri-
glyceride deposition in vivo, but also inhibits the signal
transduction mediated by AP-1 and NF-kB to relieve inﬂammation
(3). Fatty acid oxidases in the mitochondria, peroxisomes and mi-
crosomes expressed abnormally in PPAR-a knockout (KO) mice,
leading to increase of free fatty acids in plasma and excessive
accumulation of lipids in liver (4). In comparison to wild-type mice,
PPAR-a KO mice exhibited high expression levels of many inﬂam-
matory factors, as tumor necrosis factor alpha (TNF-a) and inter-
leukin 1b (IL-1b) in liver and adipose tissues (5). Fibrates are
widespread applied as PPAR-a agonists into clinic practice to
regulate plasma lipid disorders (6). Some clinic data has shown that
fenoﬁbrate plays a central role in reducing plasma and hepatic
triglyceride concentrations and transaminase activities and
improving insulin resistance in NAFLD patients in vivo (7). However,r B.V. All rights reserved.
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(EC50¼ 30 mM) (8), as well as dose-dependent side effects that have
been reported (9), there is an unsatisﬁed clinical requirement for
new PPAR-a agonists with potential speciﬁcity and safety to play
regulator roles in metabolic syndromes.
Compared with fenoﬁbrate, an endogenous lipid OEA shows a
higher afﬁnity with PPAR-a (EC50 ¼ 120 nM), which has been
indicated by using luciferase assay for PPRE and PPAR-a vectors-
transfected HEK293 cells (10). In the prior reports, this molecular
was considered as a better regulator for the treatment of obesity,
atherosclerosis and other metabolic diseases (11,12). However, the
effects and mechanisms about OEA applied to improve NAFLD have
not been reported. OEA plays an important regulatory role in lipid
metabolism and can enhance fatty acid oxidation in primary
cultured skeletal muscle cells, liver cells and cardiac myocytes. But
it does not affect fatty acid oxidation processes in similar cells
extracted from PPAR-a KOmice, which conﬁrms that OEA regulates
fatty acidmetabolism by activating PPAR-a (13). Obesity and insulin
resistance are often accompanied by lipid metabolic disorders (14),
which are turned out to be the main cause of NAFLD. As OEA has
been demonstrated to induce weight loss in association with im-
provements in body lipid metabolism, we hypothesize that OEA
may play a protective role against NAFLD. In present experiments,
we evaluated the role andmechanism of OEA on NAFLD induced via
a high fat diet (HFD) in rats. Furthermore, whether OEA can play an
improved regulatory role over the traditional PPAR-a agonist,
fenoﬁbrate, has also been studied.
Materials and methods
Materials
OEA was synthesized in our lab as previously described (15);
fenoﬁbrate, dimethyl sulfoxide (DMSO) and all other chemicals
were obtained from SigmaeAldrich (Shanghai, China). Dulbecco's
modiﬁed Eagle's medium (DMEM) and fetal bovine serum (FBS)
were purchased from Invitrogen (Shanghai, China). Lipofectamine®
2000 (Lipo2000) and Human PPAR-a Silencer Select siRNA (ID
s10880) were purchased from Invitrogen (Shanghai, China). The
chemical constituents were dissolved in saline supplemented with
5% polyethylene glycol 400 (PEG400) and 5% Tween-80 for the
in vivo studies. For the in vitro studies, OEA was dissolved in DMSO
to a concentration of 50mmol/L (stock solution) and then diluted in
the culture medium to a ﬁnal concentration of 50 mmol/L. TNF-a
and IL-6 enzyme-linked immunosorbent assay (ELISA) kits were
purchased from R&D Systems (Shanghai, China). Total cholesterol
(TC), triglycerides (TG), alanine transaminase (ALT) and aspartate
transaminase (AST) commercial assay kits were purchased from
Nanjing Jiancheng Bioengineering Institute (Nanjing, China).
Animals and diets
Male Sprague Dawley (SD) rats (250e300 g) were sourced from
Shanghai Laboratory Animal Center (Shanghai, China). All experi-
mental protocols were approved by the Committee for Animal
Research at Xiamen University. The rats were housed in a room
with controlled temperature (21e23 C), humidity (55e60%) and
lighting (12 h light/dark cycles) and given water ad libitum. Rats
were fed a HFD diet (30% fat, 2% cholesterol, 2% sugar, 0.5% choline
and 65.5% normal diet) or a normal diet (ND) for 6 weeks or 17
weeks to induce nonalcoholic fatty liver. The HFD-fed rats were
randomly divided into three experimental groups (n¼ 8 per group).
One group was treated with OEA (5 mg/kg/day; intraperitoneal
injection, i.p.) and another group was treated with fenoﬁbrate
(10 mg/kg/day; i.p.). The third group was treated with the vehicle(5% Tween-80 þ 5% PEG400 þ 90% saline). All these compounds
were treated once daily.
Liver histological studies
Fresh liver tissue was ﬁxed in 10% neutral-buffered formalin for
3 days and then embedded in parafﬁn for histological examina-
tions. Tissue sections (5 mm thick) were cut by a Leica SM2010 R
Sliding microtome (Shanghai, China) and stained with hematox-
ylineeosin (H&E); stained areas were viewed and imaged under
microscopy (Nikon, Shanghai, China).
Plasma biochemistry assays
Plasma transaminase (ALT and AST) and triglyceride (TC and TG)
concentration were measured individually by a Thermo Scientiﬁc
Multiskan GO Microplate Spectrophotometer with commercial kits
(Nanjing Jiancheng Bioengineering Institute, China). Plasma TNF-a,
IL-6 and leptin protein levels were measured using ELISA (R&D
Systems, Shanghai, China).
RNA isolation and cDNA synthesis
Liver samples were homogenized and total RNA was extracted
using the TRIzol™ isolation reagent (Invitrogen) according to the
manufacturer's recommendations. cDNA was synthesized from
total RNA using a ReverTra Ace® qPCR RT kit (Toyobo, Shanghai,
China) according to the manufacturer's instructions.
Real-time PCR
Quantiﬁcation ofmRNAwas performed on anApplied Biosystems
7300 real-time polymerase chain reaction (PCR) system using SYBR®
Premix Ex Taq™ II (Takara, Dalian, China). Primer sequences were
synthesized as follows: TNF-a, 50-GGC TCC CTC TCA TCA GTT CCA-30
(forward), 50-CGC TTGGTGGTT TGC TACGA-30 (reverse); IL-6, 50-TGC
CTT CTT GGG ACT GAT GTT G-30 (forward), 50-TGG TCT GTT GTG GGT
GGTATC C-30 (reverse); C-reactive protein (CRP), 50-TGT CTC TATGCC
CACGCTGATG-30 (forward), 50-GGC CCACCTACTGCAATACTAAAC-
30 (reverse); CPT-1, 50-AAC TTT GTG CAG GCC ATG ATG-30 (forward),
50-GGC AGA AGA TGG CGG TCG-30 (reverse); enoyl-CoA hydratase
(ECHS1), 50-ATGGCTATGCTC TTGGTG-30 (forward), 50-GTGATT TGC
CGACTG CTC-30(reverse); PPAR-a, 50-AAT CCA CGA AGC CTACCT GA-
30(forward), 50-GTC TTC TCA GCC ATG CAC AA-30 (reverse); stearoyl-
CoA desaturase-1 (SCD-1), 50-ACA TGC TCC AAG AGA TCT CCA G-30
(forward), 50-GTACTC CAGCTTGGGCGG-30 (reverse); OB-Rb, 50-GCA
TGC AGA ATC AGT GAT ATT TGG-30 (forward), 50-CAA GCT GTA TCG
ACA CTG ATT CTT C-30 (reverse); glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH), 50-ACC ACG AGA AAT ATG ACA ACT CCC-30
(forward), 50-CCA AAG TTG TCA TGGATGACC-30 (reverse). The levels
of mRNAwere normalized relative to the amount of GAPDH mRNA.
Lipid extraction and analysis
Total lipids were extracted from liver samples according to the
modiﬁed methods as previously described (16). C17:0 margaric acid
was added as an internal standard for the quantitation of fatty acids.
An Agilent 1200 Series HPLC (Agilent Corporation, MA, USA) inter-
faced to an Applied Biosystems 3200 Q-Trap triple-quadrupole linear
ion trapmass spectrometer (AppliedBiosystems/MDSSciex, Concord,
Canada) was operated during experiments. Fatty acids were sepa-
rated using a Hypersil Gold C18 column (dimensions: 250 4.6mm;
particle size: 5 mm;Thermo) elutedwith a constantmobile phase that
was composed of 5mMammoniumacetate in acetonitrile (solvent A,
65%) and 5 mM ammonium acetate in 2-propanol (solvent B, 35%);
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trometer detection was ionized by the full scan electrospray ioniza-
tion mode (ESI) and monitored in multiple reaction monitoring
(MRM)mode. The ion source temperature wasmaintained at 650 C.
Quantiﬁcations were calculated using Analyst 1.4.1 data acquisition
and processing software (Applied Biosystems/MDS Sciex).
Cell culture and RNA interference
HepG2 cells (American Type Culture Collection, Manassas, VA,
USA) were cultured in Dulbecco's modiﬁed Eagle's medium
(DMEM) supplemented with 10% fetal bovine serum (FBS). All cells
were cultured in 6-well culture plates under 37 C and 5% CO2 in an
incubator. siRNA was diluted with Opti-MEM® I to concentrations
of 20 nmol/L. Lipo2000 was mixed gently, then diluted to 5 mL in
250 mL Opti-MEM® I and incubated at room temperature for 5 min.
The diluted Lipo2000 and siRNA were mixed gently and incubated
at room temperature for 20 min and the siRNAeLipo2000 com-
plexes were added to cultured cells in 6-well culture plates and
maintained at 37 C in a 5% CO2 atmosphere in an incubator.
Statistical analysis
All statistical analyses were performed using GraphPad Prism
version 5.01 for Windows. Data are presented as the mean ± SEM
and were evaluated by one-way analysis of variance (ANOVA) fol-
lowed by Dunnett's test for multiple comparisons. P < 0.05 was
considered statistically signiﬁcant.
Results
Protective effects of OEA on HFD-induced hepatic steatosis and liver
injury
The main feature of HFD-induced NAFLD is the hepatic fat
accumulation. To assess the impact of OEA on the accumulation ofFig. 1. OEA prevented hepatocellular ballooning and reduced plasma transaminase and tri
cellular ballooning in vehicle-treated rats fed a normal diet (A), vehicle-treated rats fed a h
weeks of treatment. Graphs DeG show the effect of the vehicle or OEA on blood plasma lev
and aspartate aminotransferase (AST) (G) in rats fed a normal diet or HFD after 17 weeks
P < 0.001 compared with the control group, ## P < 0.01 compared with the control groupfat droplets, histology studies with H&E staining showed that se-
vere steatosis with a amount of fat vacuoles appeared in the rat
liver cells with HFD feeding for 17 weeks compared to that in
normal diet-fed rats (Fig. 1A and B), and OEA administration (5 mg/
kg/day, 17 weeks, i.p.) reduced the vacuoles of the lipid droplets in
liver cells of HFD-fed rats obviously (Fig. 1B and C). Consistent with
a large number of lipid droplets accumulated in the liver, HFD
induced the increase levels of triglyceride (TG) (Fig. 1D) and total
cholesterol (TC) (Fig. 1E) in rat plasma (P < 0.001), which were
reversed by OEA treatment (Fig. 1DeF, P < 0.001). Furthermore,
biochemistry analysis showed that plasma alanine aminotrans-
ferase (ALT) (Fig. 1F) and aspartate aminotransferase (AST) (Fig. 1G),
two key indicators of liver function damage, increased in HFD rats
(P < 0.01), while OEA treatment signiﬁcantly reduced the plasma
levels of ALT and AST in HFD-fed rats (Fig. 1FeG, P < 0.001).
OEA suppresses the HFD-induced inﬂammatory response
Inﬂammation has been shown to involve in the developmental
process of fatty liver. Clinical researches have shown the marked
raises of TNF-a and IL-6 levels in the liver and plasma of NAFLD
patients (17,18). To investigate OEA effect on HFD-induced inﬂam-
mation, rats were fed with HFD for 17 weeks with/without OEA
regimen (5 mg/kg, i.p.). Real-time PCR detection showed that HFD
induced the mRNA expressions of inﬂammatory cytokines including
CRP (Fig. 2A), TNF-a (Fig. 2B), and IL-6 (Fig. 2C) in the liver of SD rats,
and the changes of cytokines by HFD were reversed by OEA treat-
ment (Fig. 2AeC). In addition, biochemical analysis showed that the
induction of the plasma levels of TNF-a (Fig. 3A) and IL-6 (Fig. 3B) by
HFD were corrected by OEA treatment (Fig. 3A and B).
OEA promoted lipid catabolism genes in a PPAR-a-dependent
manner
To study the mechanism underlying OEA effect on improving
the prognosis of NAFLD, the mRNA expression of the key genesglyceride content levels in HFD-induced NAFLD in rats. H&E staining showed hepato-
igh fat diet (B) and OEA-treated rats (5 mg/kg/day; i.p.) fed a high fat diet (C) after 17
els of triglyceride (TG) (D), total cholesterol (TC) (E), alanine aminotransferase (ALT) (F)
of treatment. Vehicle, 5% PEG400/5% Tween-80 in saline; OEA, 5 mg/kg/day, i.p. ###
, *** P < 0.001 compared with the HFD group; one-way ANOVA, n ¼ 8.
Fig. 2. OEA inhibited inﬂammation in livers of NAFLD rats. Liver CRP (A), TNF-a (B) and IL-6 (C) mRNA levels following treatment with the vehicle or OEA in rats fed a normal diet or
HFD assessed by real-time quantitative PCR. Vehicle, 5% PEG400/5% Tween-80 in saline; OEA, 5 mg/kg/day, i.p. # P < 0.05 compared with the control group, ### P < 0.001 compared
with the control group, * P < 0.05 compared with the HFD group, ** P < 0.01 compared with the HFD group; one-way ANOVA, n ¼ 8.
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CPT-1, ECHS1, were determined. Real-time PCR analysis showed
that HFD diet had no effect on themRNA expressions of PPAR-a, and
ECHS-1, and down-regulated the CPT-1 gene (Fig. 4AeC), whileFig. 4. OEA normalized gene expression levels in HFD-induced NAFLD in rats. The effect of th
assessed by real-time quantitative PCR after 17 weeks of treatment. Vehicle, 5% PEG400/5% T
### P < 0.001 compared with the control group, ** P < 0.01 compared with the HFD grou
Fig. 3. OEA decreased TNF-a and IL-6 levels in plasma of NAFLD rats. TNF-a (A) and IL-6 (
treatment assessed by ELISA. Vehicle, 5% PEG400/5% Tween-80 in saline; OEA, 5 mg/kg/day
control group, * P < 0.05 compared with the HFD group, ** P < 0.01 compared with the HFadministration of OEA (5 mg/kg/day, i.p) signiﬁcantly increased the
mRNA expression levels of PPAR-a (Fig. 4A), CPT-1 (Fig. 4B), and
ECHS-1 (Fig. 4C). To further identify whether the above effect of
OEA was mediated by the PPAR-a receptor, HepG2 cells weree vehicle or OEA on mRNA levels of PPAR-a (A), CPT-1 (B), ECHS1 (C) and SCD-1 (D), was
ween-80 in saline; OEA, 5 mg/kg/day, i.p. ## P < 0.01 compared with the control group,
p, *** P < 0.001 compared with the HFD group; one-way ANOVA, n ¼ 8.
B) protein levels in the plasma of rats fed a normal diet or HFD after vehicle or OEA
, i.p. # P < 0.05 compared with the control group, ### P < 0.001 compared with the
D group; one-way ANOVA, n ¼ 8.
Fig. 5. OEA inhibited SCD-1 enzyme activity in HFD-induced NAFLD in rats. The levels of palmitic acid (16:0) and palmitoleic acid (16:1) following treatment with the vehicle or OEA
in rats fed a normal diet or HFD were detected by LCeMS. SCD-1 enzyme activity was deduced from the ratio palmitoleic acid to palmitate (16:1/16:0). Vehicle, 5% PEG400/5%
Tween-80 in saline; OEA, 5 mg/kg/day, i.p. ## P < 0.01 compared with control group, * P < 0.05 compared with HFD group, one-way ANOVA, n ¼ 8.
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0.25 mmol/L) stimulated to create an in vitro NAFLD model. The
mRNA expression levels of the nuclear receptor gene PPAR-a
(Fig. 6A) and fatty acid b-oxidation gene CPT-1 (Fig. 6B) were
examined by real-time PCR after OEA (50 mM) administration.
In vitro results showed that the expression levels of both genes
increased signiﬁcantly after OEA stimulation (P < 0.01 and P < 0.01,
respectively), while using PPAR-a RNAi, the lipogenetic promoting
effects of OEA was completely disappeared. This suggested that
OEA promoted fatty acid b-oxidation by activating PPAR-a pathway.OEA inhibited hepatic SCD-1 gene expression and protein activity in
a PPAR-a-independent manner
As SCD-1 plays an important role on lipid homeostasis in the
liver, we found that HFD induced the mRNA expression of SCD-1
(Fig. 4F) in rat liver. OEA administration (5 mg/kg/day, i.p.)
completely corrected the HFD-induced SCD-1 expression in the
liver. In addition, we further analyzed the enzyme activity of SCD-1,
assessed by the ratio of palmitic acid (16:0 PA) to palmitoleic acid
(16:1 PA), in the liver by the transition of fatty acid composition.
Liquid chromatographyemass spectrometry (LCeMS) analysis
were found that HFD signiﬁcantly increase the contents of 16:1 PA
in the liver, and the ration of 16:1 PA to 16:0 PAwas increase by that
to evaluate the SCD-1 enzyme activity. Fig. 5C showed that
comparing to HFD treatment OEA administration (5 mg/kg/day;
i.p.) inhibited the desaturation of palmitateplamitic acid, and the
ratio of 16:1/16:0 was decreased (P < 0.05). These results suggestedFig. 6. OEA promoted fatty acid b-oxidation via PPAR-a signaling, suppressed SCD-1 expressi
a siRNA transfection on mRNA expression levels of PPAR-a (A), CPT-1 (B), SCD-1 (C), assess
Vehicle, 0.1%DMSO. * P < 0.05, ** P < 0.01, *** P < 0.001, two-way ANOVA, n ¼ 6.that OEA not only reduced SCD-1 expression levels in the liver, but
also inhibited its activity signiﬁcantly especially controlled the
desaturation of palmitic acid.
In the same in vitro HepG2 cell model, we examined a change in
SCD-1 expression levels (Fig. 6C) and found that OEA treatment
down-regulated SCD-1 expression signiﬁcantly (P < 0.001), while
this inhibition effect of OEA on SCD-1 expression (P < 0.05) was still
observed with PPAR-a RNAi treatment. However, without regard to
OEA treatment, PPAR-a gene knockdown also reduced the SCD-1
gene expression levels to a high degree. These test results
showed that the regulatory role of OEAwith regard to SCD-1 down-
regulation was not mediated by the PPAR-a pathway.Roles of OEA and fenoﬁbrate in the NAFLD model
During the 17-week animal experiments, we administrated
fenoﬁbrate (10 mg/kg/day, i.p.) as positive control simultaneous
with a HFD treatment to compare the role of OEA and fenoﬁbrate
on NAFLD. The survival rate of rats treated with fenoﬁbrate was
remarkably affected during the treatment period. As shown in
Fig. S1AeD, rats in the fenoﬁbrate-treated group began to die at 14
weeks after drug administration, which had all died at 17 weeks.
Compared to the fenoﬁbrate-treated group, the remaining three
groups, including the OEA-treated group, resulted in no animal
death up to 17 weeks of treatment. To further compare the roles of
fenoﬁbrate and OEA, we re-designed a 6-week short-term experi-
ment with the same groups and treatment protocols as performed
in 17-week long-term experiment.on in a PPAR-a independent manner. The effect of OEA combined with or without PPAR-
ed by real-time quantitative PCR, on HepG2 cells. PPAR-a siRNA, 10 nM; OEA, 50 mM;
L. Li et al. / Journal of Pharmacological Sciences 127 (2015) 244e250 249During the 6-week experiment, no animal death was observed
in all groups (Fig. S1EeH). OEA (5 mg/kg/day; i.p.) and fenoﬁbrate
(10 mg/kg/day; i.p.) administration showed similar pharmacody-
namic effects with regard to less severe steatosis, decreased serum
ALT, AST levels, meliorative liver inﬂammation (Figs. S2 and 3). RT-
PCR analysis suggested that the two compounds could activate
PPAR-a and promote the b-oxidation of fatty acids (Fig. S4AeC).
Hepatic lipid homeostasis needs a balance between lipid syn-
thesis and metabolism. We then evaluated the related genes for de
novo lipogenesis, and found that OEA and fenoﬁbrate showed the
opposite effects (Fig. S4DeF). OEA reduced SREBP-1c, SCD-1, and
ACC mRNA expression levels (P < 0.05) during the 6-week period
after drug administration, while fenoﬁbrate treatment increased
the above genes expression levels signiﬁcantly (P < 0.001), which
indicated that OEA inhibited the whole system of lipogenesis.
Discussion
In this paper we have explored whether the endogenous lipid
OEA is a safe and effective lead compound to improve NAFLD
development and the mechanism of action of OEA is dissected
preliminary. Excessive consumption of HFD enhanced the devel-
opment of hepatosteatosis. Therefore, HFD-induced animal model
has been widely applied in NAFLD research (19). A 17-week long-
term experiment has been conducted to accumulate enough lipid
droplets in the liver and cause chronic liver injury for a better
observation of the effects of OEA. In this animal model, OEA was
found to play a critical role in lowering fatty degeneration of the
liver, reducing hepatocellular damage and inhibiting inﬂammation
effectively.
PPAR-a is highly expressed in liver, where it regulates multiple
genes encoding for enzymes involved in fatty acid b-oxidation
(20,21). CPT-1 is located in the mitochondrial membrane, which
can promote the transport of long-chain fatty acids into the mito-
chondria to further participate in the b-oxidation process and be-
comes a rate-limiting enzyme for fatty acid oxidation. It has been
extensively shown that fenoﬁbrate could induce higher CPT-1
expression in liver and adipose tissues by PPAR-a pathway
(22,23). The present study showed that treatment with OEA
increased the expression of CPT-1, as well as PPAR-a and ECHS1 to
promote the fatty acid oxidation process. These results suggested,
at least to some extent, the two PPAR-a agonists regulated liver
fatty acid metabolism by promoting fatty acid b-oxidation.
Stimulated de novo lipogenesis has been observed after treat-
ment with PPAR-a agonists in many experiments (24,25). In the 6-
week short-term drug administration experiment, we did observe
that fenoﬁbrate signiﬁcantly up-regulates the expression level of
SCD-1 and SREBP-1c mRNA in the rat liver as the previous studies
have been shown. But the experiment results of OEA were in
contrast to the regulatory role of fenoﬁbrate. Our results showed
that the expression level of the SCD-1 gene in the liver increased
signiﬁcantly in animals after 6 and 17-week HFD treatment and
OEA could down-regulate the expression of SCD-1 mRNA in liver
tissues signiﬁcantly. Additional investigation of liver SCD-1 enzyme
activity showed that OEA also regulated SCD-1 activity and
reversed the increased HFD-induced desaturation index (16:1/
16:0) markedly.
Leptin is a hormone secreted by adipose tissue that plays a
crucial role in energy metabolism. Some ﬁndings suggested that
down-regulation of SCD-1 is an important component of leptin's
metabolic actions (26). To estimate whether leptin signaling
pathway mediated the different regulatory role of OEA and feno-
ﬁbrate on SCD-1 expression, 6-week animal experiment has been
used to detect the plasma leptin levels and hepatic OB-Rb gene
expression (Fig. S5). As a result, both OEA and fenoﬁbrate decreasedplasma leptin levels and up-regulated the mRNA expression of OB-
Rb in livers, which indicated that the opposite effect on SCD-1
expression was irrelevant to leptin signaling pathway.
SCD-1 is also known to be regulated by PPAR-a and SREBP-1c
(27,28). To estimate whether the action of OEA on hepatic SCD-1
was mediated via PPAR-a pathway, an in vitro experiment on
HepG2 cell was conducted. The results indicated that PPAR-a
knockdown suppressed the expression of SCD-1 gene, which acted
in accordance with the known theory. But in PPAR-a RNAi group,
OEA still decreased the expression level of SCD-1 (Fig. 6), which
suggested that the down-regulation of SCD-1 by OEA was inde-
pendent of PPAR-a pathway. It was noteworthy that in the 6-week
experiment, distinct down-regulation of SCD-1, ACC as well as
SREBP-1c mRNAwas observed in OEA administration group, which
suggested that SCD-1 expression maybe under SREBP-1c signaling
control.
Administration of fenoﬁbrate increased hepatic expression of
genes involved in fatty acid b-oxidation and at the same time also
increased lipogenetic genes levels. These results are consistent with
previous reports (24,25). Another conventional PPAR-a synthetic
agonists, Wy-14643, has also showed a similar pharmacodynamic
effect (29). However, despite promoting fatty acid b-oxidation, OEA
inhibited the lipid synthetic genes expression, which would be
important to avoid hepatic lipoperoxide accumulation. Maybe, it is
the reason for high mortality occurrence only in the fenoﬁbrate-
treated 17-week long-term group.
To elucidate whether the effect of OEA on the expression of lipid
metabolism genes speciﬁc under HFD condition, we examined the
effect of OEA on above genes in rats fed normal diets (Fig. S6). After
6 h administration, real-time PCR detection shown that OEA
signiﬁcantly increased the mRNA levels of PPAR-a and CPT-1,
obviously decreased the expression of SREBP-1c and SCD-1, but
had no effect on liver ECHS1, AdipoR2 and OB-Rb expression.
Similarly results were observed after 12 h administration. These
results indicated that OEA could promote fatty acid b-oxidation and
inhibit lipogenesis both in normal and HFD-fed rats.
In conclusion, OEA, an endogenous PPAR-a agonist, has a
beneﬁcial effect on HFD-induced NAFLD in rats via promoting fatty
acid b-oxidation, and inhibiting de novo lipogenesis. It showed a
better liver protective role than fenoﬁbrate, a known clinical PPAR-
a agonist, in rat models. All these considerations suggest that OEA
may represent a potential lead compound or a promising thera-
peutic target on NAFLD.Conﬂicts of interest
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